News
Market and company headlines
VTRSAll
Loading
03:00-07:00Today2 Stories
Earnings Preview: What to Expect From Viatris' Report
Viatris will release its third-quarter earnings next week, and analysts anticipate a single-digit profit dip.
IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover Wave
ImmunityBio expects November results from a 366-patient Anktiva trial and plans a fourth-quarter FDA filing.
04:00Yesterday1 Story
08:00Oct 251 Story
12:00Oct 231 Story
07:00-16:00Oct 212 Stories
A Look Back at Generic Pharmaceuticals Stocks’ Q2 Earnings: Viatris (NASDAQ:VTRS) Vs The Rest Of The Pack
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceuticals stocks fared in Q2, starting with Viatris (NASDAQ:VTRS).
JP Morgan Maintains Neutral on Viatris, Raises Price Target to $20
JP Morgan analyst Chris Schott maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $18 to $20.
10:00Oct 191 Story
12:00-17:00Oct 162 Stories
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. RYZUMVI is currently approved in the United States for the treatment of pharmacologically-induced mydriasis and is the only commercially available FDA-approved product for that use. This approval expands the product's indications to include presbyopia.
Viatris Receives FDA Approval For RYZUMVI To Treat Presbyopia In Adults
Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in
02:00-09:00Oct 122 Stories
Viatris: Is The Pacira Deal A Game Changer? (Rating Upgrade)
Viatris Q3 earnings preview: raised 2026 EPS guidance, improving margins, and Pacira acquisition impact.
Viatris: Improved Confidence Drives M&A Action Again
Viatris has rebounded 50% YTD, driven by a return to growth and operating leverage after years of stagnation and execution issues. I rate the VTRS stock a hold.
11:00-22:00Oct 92 Stories
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents.
Pacira Biosciences' Acquisition by Viatris Unlikely to See Superior Bid, RBC Says
Pacira Biosciences' (PCRX) proposed acquisition by Viatris (VTRS) is not likely to see a superior bi
03:00-10:00Oct 92 Stories
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.
Viatris To Acquire Pacira BioSciences: What Investors Should Know
Viatris is acquiring Pacira Biosciences to boost its pain management portfolio and address revenue stagnation. Read why VTRS stock is upgraded to a hold.
07:00Oct 81 Story
08:00-11:00Oct 62 Stories
VTRS vs. AVTR: Which Stock Is the Better Value Option?
VTRS vs. AVTR: Which Stock Is the Better Value Option?
Should Value Investors Buy Viatris (VTRS) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
07:00-13:00Oct 53 Stories
UBS Maintains Buy on Viatris, Raises Price Target to $26
UBS analyst Ashwani Verma maintains Viatris (NASDAQ:VTRS) with a Buy and raises the price target from $23 to $26.
FDA Decision Watch: RHHBY, VTRS And IRD Face Key October Drug Rulings As MRK Withdraws Application
Roche has two FDA catalysts coming up for Tecentriq and Enspryng, while Viatris and Opus Genetics await a decision on expanding MR-141 into the presbyopia market.
06:00Oct 51 Story
14:00Sep 291 Story
15:00Sep 251 Story
06:00Sep 241 Story
03:00-05:00Sep 232 Stories
Oppenheimer Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $25
Oppenheimer analyst Les Sulewski initiates coverage on Viatris (NASDAQ:VTRS) with a Outperform rating and announces Price Target of $25.
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields
Analysts review high-yield healthcare stocks CVS, Viatris and Medtronic, citing ratings, price targets, dividend yields and recent company news.
20:00Sep 201 Story
06:00-10:00Sep 162 Stories
Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $13
Piper Sandler analyst David Amsellem maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $12 to $13.
Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for WAKIX® (pitolisant) for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea syndrome (OSAS) in patients receiving treatment for airway obstruction, and approval for narcolepsy (type 1 and 2 – with and without cataplexy). WAKIX is the first histamine H3 receptor antagonist/inverse agonist approved in Japan fo
03:00Sep 161 Story
10:00Sep 91 Story
10:00Sep 21 Story
10:00-13:00Aug 312 Stories
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris
Amphastar Pharmaceuticals, Sandoz and Viatris are positioned to benefit from new launches, biosimilars and a shift toward higher-value generics.
3 Cash-Producing Stocks That Concern Us
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
05:00Aug 291 Story
06:00Aug 281 Story
14:00Aug 271 Story
17:00Aug 251 Story
13:00Aug 191 Story
09:00Aug 181 Story
07:00Aug 151 Story
14:00-20:00Aug 132 Stories
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?
According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million. Under the deal terms, Harrow will pay $30 million in cash at closing, funded via cash on hand, with up to $70 million in contingent […]
Viatris (VTRS) Q2 2026 Earnings Call Transcript
Greater China surges 16% as management raises full-year guidance.
11:00Aug 121 Story
04:00-10:00Aug 112 Stories
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.
VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape Outlook
Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company expects the full year’s revenue to be around $14.75 billion, close to analysts’ estimates. Its non-GAAP profit of $0.69 per share was 15% above analysts’ consensus estimates.
16:00-22:00Aug 92 Stories
Viatris (VTRS) Is Down 6.4% After Raising 2026 Guidance And Completing Major Buyback Program
In early August 2026, Viatris Inc. reported higher second-quarter and year-to-date revenues, a six-month return to net profitability, raised its 2026 earnings guidance midpoint to US$14.75 billion, completed a US$1.15 billion share repurchase program covering 8.7% of shares, and affirmed a US$0.12 quarterly dividend. An interesting angle is that Viatris paired improved earnings and guidance with both capital returns and the FDA approval of its low-estrogen Gwyn Lo contraceptive patch,...
Viatris (VTRS) Stock May Be Below Fair Value Despite FDA Patch Approval
Viatris stock has delivered a strong 76.1% return over the past year, and the broader valuation checks still indicate the shares may be pricing in less than the company’s fundamentals could justify. Viatris is up 76.1% over the last 12 months, which puts more focus on whether the recent share price better reflects the company’s long term earnings power. Recent product news, including the FDA approval of the Gwyn Lo contraceptive patch and the agreement to transfer rights to TYRVAYA nasal...